Question: Biological Pathways And Drug Designing
gravatar for Dataminer
7.9 years ago by
Dataminer2.6k wrote:

How the current version of pathway resources (KEGG/WikiPathways etc) can contribute/aid in the development of better drugs?

drug pathway • 2.0k views
ADD COMMENTlink modified 3.6 years ago by Chris Evelo9.9k • written 7.9 years ago by Dataminer2.6k

What do you mean by "designer drugs"? Do you mean "rational drug design"?

ADD REPLYlink written 7.9 years ago by Lars Juhl Jensen11k

lets say better drugs

ADD REPLYlink written 7.9 years ago by Dataminer2.6k

lets say better drugs...

ADD REPLYlink written 7.9 years ago by Dataminer2.6k
gravatar for Giovanni M Dall'Olio
7.9 years ago by
London, UK
Giovanni M Dall'Olio26k wrote:

Well, for example, knowing which genes are associated with a biological mechanism can help to restrict the search for gene targets. If you want to develop a drug against malaria you will look at the genes involved in immunity, blood development, etc..

Moreover, if you know which genes interact together and how, you can more or less predict what will be the effect of blocking the activity of an enzyme or the interaction between two proteins.

There are a lot of examples in the literature about using pathways to design better drugs... for example L. G. Boros and T. F. Boros Use of Metabolic Pathway Flux Information in Anticancer Drug Design

ADD COMMENTlink written 7.9 years ago by Giovanni M Dall'Olio26k

Finally I have an answer :)

ADD REPLYlink written 7.9 years ago by Dataminer2.6k
gravatar for Chris Evelo
3.6 years ago by
Chris Evelo9.9k
Maastricht, The Netherlands
Chris Evelo9.9k wrote:

While @Giovanni's answer is correct I can add a bit more information about what we were actually asked to do around WikiPathways by pharma.

  1. By making WikiPathways content available as RDF we were able to load in the Open PHACTS linked data resource. In this way you can immediately look for things like "drug that hit targets (from ChEMBL) that are in pathways (from WikiPathways) that contain genes related to specific diseases (from DisGeNET)". (This was part of the original Open PHACTS IMI project).
  2. By improving the way we capture directionality of interaction in pathways you can look for drug targets that are up or downstream from your target of interest. (This is part of the second stage of the project).

Finally the BridgeDb identifier mapping framework we use at WikiPathways and in the PathVisio pathway analysis tool turned out to be very useful for semantic web identifier mapping needed in the Open PHACTS project.

ADD COMMENTlink written 3.6 years ago by Chris Evelo9.9k
Please log in to add an answer.


Use of this site constitutes acceptance of our User Agreement and Privacy Policy.
Powered by Biostar version 2.3.0
Traffic: 2246 users visited in the last hour